Pete Salzmann, Immunovant CEO

Im­muno­vant takes on ar­genx, J&J with plans to test FcRn in­hibitor in mul­ti­ple par­al­lel tri­als af­ter PhI win 

Im­muno­vant is gear­ing up to start a slate of mid-stage as well as piv­otal tri­als for its fol­low-on au­toim­mune drug, IMVT-1402, af­ter con­firm­ing what it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.